<DOC>
	<DOC>NCT01271725</DOC>
	<brief_summary>The general aim of this study is to investigate the efficacy and safety of afatinib (BIBW 2992) alone and in combination with weekly paclitaxel or weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed HER2-targeted treatment in the neoadjuvant or adjuvant setting</brief_summary>
	<brief_title>LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criteria: 1. Female patients &gt;=18 years with proven diagnosis of HER2overexpressing, histologically confirmed breast cancer 2. Stage IV metastatic disease 3. At least one measurable lesion according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1). Skin, bone and brain lesions are considered nontarget lesions 4. Must have failed or progressed on either trastuzumab or lapatinib or trastuzumab and lapatinib treatment in the neoadjuvant and/or adjuvant setting Exclusion criteria: 1. Prior first line therapy for metastatic breast cancer 2. Known preexisting interstitial lung disease 3. Active brain metastases 4. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to trial treatment. 5. Cardiac left ventricular function with resting ejection fraction of less than 50%. 6. Prior treatment with EGFR/HER2targeted small molecules or antibodies other than trastuzumab and lapatinib in the neoadjuvant or adjuvant setting 7. Prior treatment with paclitaxel in the past 12 months 8. Must not have received prior vinorelbine treatment 9. Inadequate hepatic, renal and haematologique organ function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>